Gilead And Arcus Biosciences Establish 10-Year Partnership To Co-Develop And Co-Commercialize Next-Generation Cancer Immunotherapies; Arcus To Receive $175M Up Front And $200M Equity Investment Plus Up To $1.6B In Potential R&D Funding+Milestones

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!